Edwin M. Posadas, Meghan S. Liel, Virginia Kwitkowski, Lori Minasian, Andrew K. Godwin, Mahrukh M. Hussain, Virginia Espina, Bradford J. Wood, Seth M. Steinberg and Elise C. Kohn A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer Cancer 109
Version of Record online: 1 MAR 2007 | DOI: 10.1002/cncr.22545
Gefitinib treatment for ovarian cancer inhibited the activity of the epidermal growth factor receptor (EGFR) in >50% of the patients in this study. The modulation of EGFR activity was correlated with gefitinib toxicity, and the current results indicated that EGFR inhibition is inadequate as a sole molecular therapeutic target in ovarian cancer.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field